The Father Of Medical Cannabis Research Celebrates His 90th Birthday At CannX

CannX 2020 Virtual Conference, 26 October 2020 Online

ISRAEL:  CannX has proven itself time and time again as the central meeting point for exploring the latest developments in medical cannabis. With top quality of the conference program and the leading international speakers, CannX Virtual 2020 will provide the latest in scientific research, agricultural practices and innovation, and business opportunities. Cannabis sativa has a long history as a medicinal plant and has shown therapeutic effect in patients with pain, nausea, posttraumatic stress disorder, cancer, epilepsy, glaucoma and many more conditions.

“I believe cannabinoids represent a medical treasure waiting to be discovered,” said Prof. Raphael Mechoulam, Conference President.

This year, CannX will include a special celebration in honor of Raphael Mechoulam, the Father of Medical Cannabis Research. Since the inception of his research in the 60s, Professor Mechoulam has been nominated for over 25 academic awards, including the Heinrich Wieland Prize (2004), an Honorary doctorate from Complutense University (2006), the Israel Prize in Exact Sciences – _Chemistry (2000), the Israel Chemical Society Prize for excellence in research (2009) and EMET Prize in Exact Sciences – Chemistry (2012). The honorary session will include a one-on-one interview of Prof. Mechoulam by Dr. Dedi Meiri and several surprises.

The CannX platform is dedicated to advancing scientific knowledge and practice in the emerging field of medical cannabis. With a program designed to showcase recent research and analyze real-world applications, the conference provides a unique opportunity for scientists, clinical researchers, start-ups, and established industry companies to form new collaborations and discuss the potential impact of the latest findings.

CannX 2020 will be a virtual conference, providing access to content whenever and wherever the attendees are located, thus ensuring interaction with a uniquely diverse professional audience base. The program has been submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and is pending CME accreditation. Session highlights include:

  • Women in the Forefront of Cannabis Innovation
  • The Interplay of Science, Business and Law
  • Cannabinoids and the Elderly
  • Medical Cannabis and the Role of Pharmacists: The Israeli Experience
  • COVID-19, CBD and Cannabis

View the full programs here:

 

Thousands Of Peer-Reviewed Studies Specific To Medical Cannabis Have Been Published Over Past Decade

ISRAEL: The total number of peer-reviewed scientific papers dedicated to cannabis, and the therapeutic use of cannabis in particular, has increased exponentially in recent years, according to data published the journal Population Health Management.

Israeli researchers assessed trends in the number of scientific publications specific to cannabis as compared to all scientific publications during the years 2000 to 2017. They reported: “The overall annual number of scientific publications … increased 2.5 times between 2000–2017 from 531,664 to 1,282,229. In contrast, the corresponding number for publications on cannabis increased 4.5 times … and increased 9-fold for publications on medical cannabis.”

Overall, authors identified just over 29,000 cannabis-centric scientific papers published during the study period, with over 3,300 of those dedicated to the subject of medical marijuana. Papers specific to medical cannabis were most likely to address its use in the treatment of HIV, chronic pain, multiple sclerosis, nausea, or epilepsy.

Over 60 percent of the papers were classified as “original research,” and 66 percent of all scientific papers originated from authors in the United States.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Trends in publications in medical cannabis from the year 2000,” appears in Population Health Management.

Tikun Olam Teams With iaso To Serve Puerto Rico

PUERTO RICO: Tikun Olam will soon have a presence in Puerto Rico, according to a company press release. Through an exclusive licensing agreement with iaso Corporation,  a leading San Juan-based science and technology company, Tikun products and strains, including the widely researched high-CBD Avidekel, will be distributed s throughout the Commonwealth in 2019.  The arrangement with iaso is the tenth struck in the United States by Tikun Olam’s US joint venture, TO Global.
iaso is Puerto Rico’s only all-indoor cultivation facility, employing soil-less, aeroponic technology.

Tikun products to be distributed throughout PR in 2019.

Tikun products to be distributed throughout PR in 2019.

“iaso is an ideal partner for Tikun’s values and mission,” says Tikun USA CEO Bernard Sucher. “César Cordero-Krüger has accomplished so much for his community, in business and philanthropy.  We are privileged to work with his team of professionals dedicated to advancing the science of cannabis.”

“Tikun’s proprietary cultivars are shown to treat patients in a safe, effective, and consistent manner,” says iaso founder and CEO César Cordero-Krüger. “This partnership advances iaso’s mission to become a trusted provider of cannabis products to Puerto Rican patients.”